Calcinosis cutis  is a type of calcinosis wherein calcium deposits form in the skin. A variety of factors can result in this condition. The most common source is dystrophic calcification, which occurs in soft tissue as a response to injury. In addition, calcinosis is seen in Limited Cutaneous Systemic Sclerosis, also known as CREST syndrome (the "C" in CREST). In dogs, calcinosis cutis is found in young, large breed dogs and is thought to occur after a traumatic injury. Causes
Calcinosis may result from a variety of causes such as:

Trauma to the region
Inflammation (bug bites, acne)
Varicose veins
Infections
Tumors (malignant or benign)
Diseases of connective tissue
Hypercalcemia
HyperphosphatemiaCalcinosis cutis is associated with systemic sclerosis. Diagnosis
Types
Calcinosis cutis may be divided into the following types:: 527–530 
Dystrophic calcinosis cutis
Metastatic calcinosis cutis
Iatrogenic calcinosis cutis
Traumatic calcinosis cutis
Idiopathic calcinosis cutis
Idiopathic scrotal calcinosis
Subepidermal calcified nodule
Tumoral calcinosis
Osteoma cutis

Treatment
Intralesional corticosteroids may be beneficial. Colchicine has been shown to be effective in certain populations. The efficacy of other treatments, such as magnesium or aluminum antacids, sodium etidronate, diphosphonates and diltiazem is unclear, but they have been reported to be serviceable in refractory calcinosis. Surgical options may be considered, particularly if there is associated ulceration. Gallery
See also
Calcinosis
List of cutaneous conditions

References


== External links ==
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, a type of white blood cell cancer, in combination with other drugs. It is taken by mouth in the form of capsules. Common side effects include diarrhea, constipation and low platelet count. Like the older bortezomib (which can only be given by injection), it acts as a proteasome inhibitor, has orphan drug status in the US and Europe, and is a boronic acid derivative. The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November 2016. Medical uses
Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adults after at least one prior therapy. There are no experiences with children and youths under 18 years of age.The study relevant for approval included 722 people. In this study, ixazomib increased the median time of progression-free survival from 14.7 months (in the placebo+lenalidomide+dexamethasone study arm including 362 people) to 20.6 months (under ixazomib+lenalidomide+dexamethasone, 360 people), which was a statistically significant effect (p = 0.012). 11.7% of patients in the ixazomib group had a complete response to the treatment, versus 6.6% in the placebo group. Overall response rate (complete plus partial) was 78.3% versus 71.5%.A phase 3 study demonstrated a significant improvement in progression-free survival (PFS) with ixazomib-lenalidomide-dexamethasone (IRd) compared with placebo. High-risk cytogenetic abnormalities were defined as del(17p), t(4;14), and/or t(14;16); additionally, patients were assessed for 1q21 amplification.